Trials / Completed
CompletedNCT02477475
Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
NEXIUM Capsule Specific Clinical Experience Investigation (S-CEI) to Investigate Treatment Response to NEXIUM in Patients With Reflux Esophagitis (RE) - Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,595 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.
Detailed description
Primary objective To investigate treatment response to NEXIUM in patients with reflux esophagitis (RE). Secondary objectives To investigate following items in patients with RE: 1. Patient satisfactory level of the treatment for RE 2. Health-related quality of life (HRQOL) 3. Severity and frequency of RE symptoms reported by physicians 4. Endoscopic healing rate 5. Development of ADRs
Conditions
Timeline
- Start date
- 2015-07-07
- Primary completion
- 2017-02-20
- Completion
- 2017-02-20
- First posted
- 2015-06-22
- Last updated
- 2017-06-21
Locations
47 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02477475. Inclusion in this directory is not an endorsement.